Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Saturday, November 7, 2026

Back to the front page

From X

@aleabitoreddit

Serenity on X

So two things: 1. I'm now fundamentally positive on $IREN post Mirantis acquisition and after their recent earnings. Their operating outlook and ability to finance has looked more compelling. 2. That doesn't always translate to appreciating share price and ROI to shareholders. I have caution regarding their existing $6B ATM, which now has $2.37B left (so they have been going through it). As well as CEO executive compensation, which I'd argue would be more beneficial if this were done through appreciating share prices rather than dilution. Obviously optics on their NBA Warriors deals are very bad while they're unprofitable... but I'd treat this as noise relative to the scale of the ATM overhang + executive comp. So a lot of weighing different float + market dynamics vs. operational business, but I'd argue this is something that still can be addressed.
@aleabitoreddit

Serenity on X

Even with current narratives like biotech eg. $TWST, there's 100%+ Y/Y growth from their AI testing segment with Anthropic. But if you look at company overall revenue projections, they're only calling for double revenue growth by 2031 (implying 15% annual growth). I'm sure they can beat, but this seems relatively slow compared to AI supply chains growing hundreds to 1000% Y/Y and seeing record levels of net income growth Q/Q. Not all bottlenecks have the same economic impact the way hyperscaler capex in AI supply chains does.
@calvinblissett

Calvin Blissett on X

$PDEX: Pro-Dex (PDEX) makes powered surgical handpieces (drivers and shavers) used mainly in orthopedic, thoracic (chest), and CMF (face/skull) surgeries. They design, build, and repair them primarily for medical device OEMs (one big customer drives most sales), plus some precision machining for aerospace/defense after a 2026 acquisition.⁠ New/upcoming products: Ongoing next-generation orthopedic handpiece for their largest customer (contract through 2028). Helios Pro: latest off-the-shelf CMF/cranial driver with their adaptive torque-limiting software (released for production). Articulating attachment (in development; targeting production spring/summer 2027). Monogram validation units (with Monogram Technologies/Zimmer Biomet; expected later in FY2027). Other roadmap items include a spinal driver and smart driver. Quick Pitch Market Cap $202m=Enterprise Value. Warren Buffett's Owner's Earnings of $13.45m resulting in a 15x multiple. W/C consistently a drag on cashflow. Feb 2026 acquired APM getting them into aerospace and defense. Repair revenue (probably high margin reoccurring) declining as largest customer shifts away from legacy devices. CEO been with co since 2006 and CEO since 2015. CFO been CFO since 2015
@calvinblissett

Calvin Blissett on X

$EMBC: Embecta (EMBC), spun out of Becton Dickinson in 2022, makes the pen needles and syringes people with diabetes use to inject insulin. Its U.S. pen needle business is shrinking from lost share and price cuts, and more patients are moving from daily insulin shots to weekly GLP-1s. To offset that, it is selling its needles inside the boxes of generic GLP-1 drugs, already launched in India, Canada and Brazil and targeted at $100M+ in revenue by 2033. It is also launching cheaper needles and syringes for new markets and buying into other drug-delivery products beyond insulin. Quick Pitch $350m Market Cap/$1.62B Enterprise Value. Less than 3x P/E. Warren Buffett Owners Earnings of $122m ex SBC. Cut dividend switched to $100m Buyback authorization that's being used. CEO/CFO/Director/CLO all bought August 12th
@calvinblissett

Calvin Blissett on X

$AIRT: Air T is a holding company for aviation businesses. Its companies fly cargo and regional feeder routes, sell and repair aircraft parts, and provide airport equipment, software, and aircraft leasing. Air T owns cargo/feeder flying, aircraft parts and repair, airport equipment/software, and leasing businesses. At $27.70, market cap is about $75m. Enterprise value is about $304m including debt, or ~$351m including leases, earnouts, and minority claims. FY25 cash flow less all capex was $7.8m: a tempting 9.6x market-cap multiple. But working capital contributed ~$22m of cash that year; adjusting for it makes that owners’ earnings proxy negative ~$14.6m. FY26 cash flow less capex was -$41.5m. FY26 net income included a $111m noncash bargain-purchase gain—not operating earnings. No open-market common-stock insider buys found; a July Form 144 tied to CEO Nick Swenson proposed selling 10k preferred securities, which doesn’t confirm a completed sale. Rex could drive growth, but integration, debt, inventory, thin margins, and fuel costs are risks. Air cargo demand is growing: IATA reported +4.4% in August.
@calvinblissett 1 click

Calvin Blissett on X

$BLBD ~$60 Blue Bird makes the yellow school buses. It’s one of only three big US makers (vs Thomas Built and IC Bus) and the leader in propane and electric buses. Districts buy them with local budgets and state/federal grants, and keep them ~15 years. ~$2.1B market cap, ~0 net debt. ~8.5x FY26 EBITDA ($247M guide), ~6% FCF yield. The bear case was EV subsidies running out. A VIC short at $57 in Aug ‘25 said FY27 EBITDA would fall to $92M. 15 months later: 776 EVs still in backlog, ~14% margins, price per bus +5.7%. 8x flat EBITDA = ~$57, so today’s price assumes zero growth. You get for free: A full year of Micro Bird, its small-bus arm ($16.5M EBITDA in its first quarter owned) Ford F-53/F-59 chassis deal (the frame RVs and delivery vans are built on), $1.4B added TAM, production starts 2028 Risks: legacy units -4.6% YTD, dealers say EV grant activity has “whittled down,” FY27 estimates getting cut. Q4 + FY27 guide ~Nov 23.
@aleabitoreddit

Serenity on X

I'm going to give a contrarian take on Neoclouds like $NBIS and say the theme looks compelling after the valuation crash. Since there's a reason why Elon's $SPCX is heavily focused on this market full of "guppies" that would die: He sees how attractive the economics are after selling compute to $GOOGL and Anthropic. And this is reflected by his actions not words, from SpaceX's recent $40B financing for GPUs procurement. $AMZN, $MSFT, and even $META also see how profitable the economics are and are accelerating their AI DC buildouts. I'd argue if a Neocloud has: - Close relationships with $NVDA + others for allocations - Existing contracted capacity + permitting - Well funded counterparties, such as Hyperscalers. - Attractive economics, such as financing their procurement correctly (not the way $CRWV has with high debt interest unless they refinance). Then I think they'll do just fine... However, the bigger worry is more toward newer players starting financing or the permitting process, since barrier to entry has now become extremely high. For financing, read through on $IREN earnings has shown public Neoclouds can adapt extremely well to tight markets: As seen with their 90% prepayments for GPU capex on a 5Y deal. Their older H100 GPUs recontracted at double their previous pricing and 12% higher contracted pricing also point against depreciation fears. And in the case DC buildouts slow from permitting delays... it heavily favors some over others. Rosenblatt's recent note for example stated they see little risk with $NBIS primary buildout that was in Missouri, Pennsylvania, and South Carolina. And there's probably less risk with developers in places like Australia. Markets have also show this infinite compute arbitrage can't go on forever, hence the reluctance to further finance capex, via things like ATMs. But ironically, tighter financing and hypothetical restrictive permitting would increase the competitive advantage of established neoclouds. And create a larger moat against newer DC developers.

Investor Letters

All letters

Entravision Q3 Update

Entravision’s Q3 ad-tech revenue reached $177.2 million, up 133% year over year, while total revenue rose 88% to $226.3 million and diluted…

EVC $832M
The Value Road 4 clicks

GREAT DEC-TECTIVE WORK

Diversified Energy reported $255.6 million of “true” nine-month free cash flow, while its $1.8 billion Birch acquisition would shift…

DEC $900M
The Oak Bloke 2 clicks
BKV · long

Bkv CORP

BKV Corp, public for less than two years, is an underfollowed natural-gas producer pursuing early-stage projects and a transition.

BKV $2.2B
Value Investors Club 1 click

Paxman (PAX.ST)

Paxman sells chemotherapy scalp-cooling systems, expanding US reimbursement and utilization after acquiring its largest competitor in 2025.

PXMBF $1.5B
Healthy Stock Picks

AAON

AAON shares have fallen 45% from November 2024 highs as core HVAC bookings weaken, while BASX supplies hyperscale data-center growth.

AAON $5.7B
Kairos Research

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 74 of 277

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

359 firms

Sectors

Ordered by how often our editor reaches for them.